New Strong Buy Stocks for November 16th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Entera Bio ENTX: This clinical-stage biopharmaceutical company which focuses on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need, has seen the Zacks Consensus Estimate for its current year earnings increasing 20.3% over the last 60 days.

Entera Bio Ltd. Price and Consensus

Entera Bio Ltd. Price and Consensus
Entera Bio Ltd. Price and Consensus

Entera Bio Ltd. price-consensus-chart | Entera Bio Ltd. Quote

Neuronetics STIM: This commercial-stage medical device company which focuses on design, development, and marketing products for patients who suffer from psychiatric disorders, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.0% over the last 60 days.

Neuronetics, Inc. Price and Consensus

Neuronetics, Inc. Price and Consensus
Neuronetics, Inc. Price and Consensus

Neuronetics, Inc. price-consensus-chart | Neuronetics, Inc. Quote

Fabrinet FN: This company that provides precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers and sensors,has seen the Zacks Consensus Estimate for its current year earnings increasing 7.6% over the last 60 day.

Fabrinet Price and Consensus

Fabrinet Price and Consensus
Fabrinet Price and Consensus

Fabrinet price-consensus-chart | Fabrinet Quote

Angion Biomedica ANGN: This late-stage biopharmaceutical company which focuses on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.

Angion Biomedica Corp. Price and Consensus

Angion Biomedica Corp. Price and Consensus
Angion Biomedica Corp. Price and Consensus

Angion Biomedica Corp. price-consensus-chart | Angion Biomedica Corp. Quote

Futu Holdings FUTU: This technology company which offers a digitized brokerage platform, has seen the Zacks Consensus Estimate for its current year earnings increasing 1.8% over the last 60 days.

Futu Holdings Limited Sponsored ADR Price and Consensus

Futu Holdings Limited Sponsored ADR Price and Consensus
Futu Holdings Limited Sponsored ADR Price and Consensus

Futu Holdings Limited Sponsored ADR price-consensus-chart | Futu Holdings Limited Sponsored ADR Quote

 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Angion Biomedica Corp. (ANGN) : Free Stock Analysis Report
 
Fabrinet (FN) : Free Stock Analysis Report
 
Entera Bio Ltd. (ENTX) : Free Stock Analysis Report
 
Neuronetics, Inc. (STIM) : Free Stock Analysis Report
 
Futu Holdings Limited Sponsored ADR (FUTU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research